## David T Miyamoto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8948973/publications.pdf

Version: 2024-02-01

40 papers 6,423 citations

249298 26 h-index 40 g-index

40 all docs

40 docs citations

40 times ranked

10625 citing authors

#	Article	lF	CITATIONS
1	Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition. Cancer Research, 2022, 82, 1084-1097.	0.4	2
2	Bladder preservation: Translating discovery for clinical impact in urothelial cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 201-208.	0.8	2
3	Immunotherapy Combined With Radiation Therapy for Genitourinary Malignancies. Frontiers in Oncology, 2021, 11, 663852.	1.3	19
4	Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. European Urology, 2021, 79, 762-771.	0.9	47
5	Noncanonical Wnt as a prognostic marker in prostate cancer: "you can't always get what you Wnt― Expert Review of Molecular Diagnostics, 2020, 20, 245-254.	1.5	4
6	PIK Carefully, AKT Accordingly: Towards Precision Medicine in Prostate Cancer. European Urology, 2020, 78, 845-846.	0.9	1
7	Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. European Urology Oncology, 2020, 3, 420-423.	2.6	29
8	Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. European Urology, 2019, 76, 59-68.	0.9	112
9	COX-2 mediates tumor-stromal prolactin signaling to initiate tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 5223-5232.	3.3	34
10	Molecular Characterization of Neuroendocrine-like Bladder Cancer. Clinical Cancer Research, 2019, 25, 3908-3920.	3.2	71
11	Reply from Authors re: Ananya Choudhury, Peter J. Hoskin. Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. Eur Urol 2019;76:69–70. European Urology, 2019, 76, 71-72.	0.9	2
12	Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2467-2472.	3.3	131
13	Clinical needs assessment for sexual health among cancer patients receiving pelvic radiation: Implications for development of a radiation oncology sexual health clinic. Practical Radiation Oncology, 2018, 8, 206-212.	1.1	3
14	Molecular analysis of circulating tumors cells: Biomarkers beyond enumeration. Advanced Drug Delivery Reviews, 2018, 125, 122-131.	6.6	21
15	An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. Cancer Discovery, 2018, 8, 288-303.	7.7	107
16	Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. Lancet Oncology, The, 2018, 19, e683-e695.	5.1	74
17	A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. Cancer Discovery, 2018, 8, 1286-1299.	7.7	85
18	An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1123-1128.	3.3	133

#	Article	IF	CITATIONS
19	Expression of $\hat{l}^2$ -globin by cancer cells promotes cell survival during blood-borne dissemination. Nature Communications, 2017, 8, 14344.	5.8	96
20	Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells. Nature Communications, 2017, 8, 1733.	5.8	53
21	Branched Chain RNA <i>In Situ</i> Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer. Clinical Cancer Research, 2017, 23, 363-369.	3.2	23
22	Single-Cell Analysis of Circulating Tumor Cells as a Window into Tumor Heterogeneity. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 269-274.	2.0	40
23	Genomic Instability Is Induced by Persistent Proliferation of Cells Undergoing Epithelial-to-Mesenchymal Transition. Cell Reports, 2016, 17, 2632-2647.	2.9	93
24	The promise of circulating tumor cells for precision cancer therapy. Biomarkers in Medicine, 2016, 10, 1269-1285.	0.6	11
25	Cell-free and circulating tumor cell–based biomarkers in men with metastatic prostate cancer: Tools for real-time precision medicine?. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 490-501.	0.8	11
26	Outcomes with image-based interstitial brachytherapy for vaginal cancer. Radiotherapy and Oncology, 2016, 120, 486-492.	0.3	42
27	Deformability of Tumor Cells versus Blood Cells. Scientific Reports, 2015, 5, 18542.	1.6	104
28	RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science, 2015, 349, 1351-1356.	6.0	614
29	Circulating tumour cells—monitoring treatment response in prostate cancer. Nature Reviews Clinical Oncology, 2014, 11, 401-412.	12.5	110
30	Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis. Cell, 2014, 158, 1110-1122.	13.5	1,960
31	Single-Cell RNA Sequencing Identifies Extracellular Matrix Gene Expression by Pancreatic Circulating Tumor Cells. Cell Reports, 2014, 8, 1905-1918.	2.9	449
32	Weight Gain on Androgen Deprivation Therapy: Which Patients Are at Highest Risk?. Urology, 2014, 83, 1316-1321.	0.5	17
33	Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells. Science Translational Medicine, 2013, 5, 179ra47.	<b>5.</b> 8	910
34	Concurrent Chemoradiation for Vaginal Cancer. PLoS ONE, 2013, 8, e65048.	1.1	58
35	Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer. Cancer Discovery, 2012, 2, 995-1003.	7.7	257
36	Molecular Predictors of Local Tumor Control in Early-Stage Breast Cancer. Seminars in Radiation Oncology, 2011, 21, 35-42.	1.0	15

3

#	Article	IF	CITATION
37	Outcomes and Tolerability of Chemoradiation Therapy for Pancreatic Cancer Patients Aged 75 Years or Older. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1171-1177.	0.4	34
38	Isolation and Characterization of Circulating Tumor Cells from Patients with Localized and Metastatic Prostate Cancer. Science Translational Medicine, 2010, 2, 25ra23.	5.8	474
39	The kinesin Eg5 drives poleward microtubule flux in Xenopus laevis egg extract spindles. Journal of Cell Biology, 2004, 167, 813-818.	2.3	168
40	Dynamics of the mitotic spindlepotential therapeutic targets. Progress in Cell Cycle Research, 2003, 5, 349-60.	0.9	7